HITLAB, a global leader in digital health innovation and evidence generation, announced a strategic partnership with Immunogenik, Inc., a biotechnology company developing novel therapeutic platforms for aggressive cancers such as glioblastoma (GBM) and lung cancer brain metastasis.


